Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENMD-2076 in platinum resistant ovarian cancer
NCT01104675Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2010
- Primary completion
- Aug 2011
- Countries
- 2
- Sponsor
- CASI Pharmaceuticals, Inc.
- Modality
- Small Molecules
- Drugs
- enmd-2076
- Conditions
- ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
01
Overview
Phase 2, open-label, single-arm trial of enmd-2076 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by CASI Pharmaceuticals, Inc. Primary endpoint: Progression Free Survival rate at 6 months. Started Apr 2010; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
ENMD-2076
Experimental arm receiving ENMD-2076
03
Who it enrols
Patients with platinum-resistant ovarian, fallopian, or peritoneal cancer, ECOG 0-1, and adequate organ function. Excludes patients with uncontrolled hypertension or requiring multiple antihypertensives.
04
Endpoints
Primary
Progression Free Survival rate
Secondary
Objective Response Rate
Duration of Response
Overall Survival
Safety and Tolerability
Beyond the preview
Go deeper on NCT01104675.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01104675.